Flavonolignan

Other Names

flavono-lignanflavonoid lignanflavonoid-phenylpropanoid hybridflavonolignanshybrid lignannon-conventional lignanplant polyphenol lignan hybridpolyphenolic lignan

Synopsis

Flavonolignan: A Comprehensive Reference

1. Identity, Classification, and Nomenclature

Flavonolignans (also spelled flavonolignans) are a class of natural phenolic compounds. Flavonolignans are natural phenols composed of a part flavonoid and a part phenylpropane. More precisely, structurally, flavonolignans are composed of a flavonoid unit (taxifolin) and a phenylpropane unit (coniferyl alcohol), linked together by an oxeran ring. This hybrid structure distinguishes them from pure flavonoids or pure lignans, placing them at the intersection of two major polyphenol classes.

Flavonolignans are formed by combination of flavonoid and lignan structures. This occurs by oxidative coupling processes between a flavonoid and a phenylpropanoid, usually coniferyl alcohol. Different derivatives of flavonolignans were listed, fused phenylpropanoid unit with dioxane ring, or cyclic ether, or simple ether side chain, or lactone, and so on.

The term "flavonolignan" is used both for the class as a whole and in the context of their best-known complex: silymarin, the standardized extract derived from Silybum marianum (milk thistle). The active ingredients of milk thistle fruits are flavonolignans, collectively known as silymarin. Silymarin is a mixture of flavonolignans extracted from the seeds, commercialized in standardized form, and widely used in drugs and dietary supplements.

Although silymarin-derived flavonolignans are by far the most studied, flavonolignans are not exclusive to Silybum marianum. From the literature survey, 88 constituents from natural resources were identified. Other botanical sources documented in the literature include the flavonolignans tricin 4'-O-(erythro-beta-guaiacylglyceryl) ether and tricin 4'-O-(threo-beta-guaiacylglyceryl) ether, which can be isolated together with their 7-O-glucosides in the leaves of Hyparrhenia hirta. Published sources also reference flavonolignan-containing species including Hydnocarpus wightjana, Verbascum sinaiticum, Lancea tibetica, Nelumbo nucifera, and Lepidium meyenii, among others recorded in review literature.

2. Principal Botanical Source: Silybum marianum

Silybum marianum (L.) Gaertn., commonly called milk thistle, is a member of the Asteraceae (daisy) family and is the overwhelmingly dominant commercial source of flavonolignans. Today, the species is widely distributed across central and southern Europe, North and South America, South Africa, and Australia, often thriving in disturbed soils, roadsides, pastures, and agricultural fields. In many regions, it is considered an invasive weed due to its vigorous growth, competitive ability, and capacity to form dense stands that outcompete native vegetation. Despite this, its medicinal significance has ensured its continued cultivation and use on a global scale.

The primary part used medicinally is the fruit (colloquially called the "seed"). Extracts of milk thistle (Silybum marianum, Asteraceae) have been recognized for centuries as remedies for liver and gallbladder disorders. The active constituents of milk thistle fruits are flavonolignans, collectively known as silymarin.

The total silymarin content of the dried fruit varies considerably by chemotype and growing conditions. Besides differences in total silymarin content (0.8%–4.9%), three distinct chemotypical variations in fruit flavonolignan regioisomer composition in the cultivars have been observed.

3. Key Constituent Flavonolignans and Chemical Composition of Silymarin

Silymarin is not a single compound but a mixture of related flavonolignans and at least one flavonoid. Initially silymarin was considered to be a pure compound (7-chromanol-3-methyl-taxifolin) but later introduced HPLC methods quantitatively determined 7 flavonolignans from the silymarin mixture (silybin A, silybin B, isosilybin A, isosilybin B, silychristin, isosilychristin and silydianin) plus one flavonoid (dihydroquercetin) in addition to fatty acids and other polyphenolic compounds.

The precise identities of the major constituents, as confirmed using PubChem, are as follows: the primary bioactive constituents of Silybum marianum (milk thistle), collectively referred to as silymarin, are predominantly flavonolignans namely silybin A (PubChem CID: 31553), silybin B (PubChem CID: 1548994), isosilybin A (PubChem CID: 11059920), isosilybin B (PubChem CID: 10885340), silydianin (PubChem CID: 11982272), and silychristin (PubChem CID: 441764) alongside flavonoids such as taxifolin (PubChem CID: 439533) and quercetin (PubChem CID: 5280343), as well as other polyphenolic compounds.

Silybin (silibinin) is the principal and most pharmacologically studied component. Silybin A and silybin B together constitute silybin, the principal component of silymarin (40%–60%). Of these, silibinins A and B make up 50% of silymarin and are thought to be the most therapeutically active components responsible for the majority of therapeutic effects.

The four flavonolignans most commonly identified in quantitative studies are silybin, isosilybin, silydianin, and silychristin. Silybin A, silybin B, and silychristin are positively correlated as are silydianin, isosilychristin, and isosilybin B in terms of their biosynthetic relationships. Except for silydianin, they occur in nature as two stereomers.

Individual components beyond silybin have distinct biological profiles. Silychristin is the next most copious flavonoid next to silybin in the extracts of silymarin, which has also presented antioxidant activity and non-cytotoxic effect against different cancer cell lines. Isosilybin A and B have shown anti-prostate cancer activity by executing cell cycle arrest and cell apoptosis. Taxifolin has emerged as a unique bioactive flavonoid, showing promising inhibitory effects against oxidative stress, inflammation, hyperglycemia, and various malignancies.

Additionally, the 2,3-dehydro derivatives of several flavonolignans (such as 2,3-dehydrosilybin, 2,3-dehydrosilychristin, 2,3-dehydrosilydianin) are minor constituents that have attracted increasing research attention. Several properties of silymarin extract have been attributed to their three major flavonolignans (silybin, silychristin, and silydianin) and their 2,3-dehydro derivatives. Experimental findings have suggested that the antioxidative and protective activities of these compounds could be due to their ability to activate nuclear factor erythroid 2-related factor 2 (Nrf2).

4. Traditional and Historical Use

Milk thistle has a rich history of medicinal use dating back more than 2,000 years. Extracts of milk thistle have been recognized for centuries as remedies for liver and gallbladder disorders.

The earliest documented uses draw from ancient Mediterranean civilizations. The earliest records of milk thistle's use date back to ancient Greece. The Greek physician Dioscorides documented the plant in his seminal work De Materia Medica, describing its use for treating snake bites and liver complaints. He noted that the plant's leaves, when crushed, produced a milky sap — hence the name "milk thistle" — and that this sap had a soothing effect on irritated skin and internal organs. The Roman naturalist Pliny the Elder echoed Dioscorides' observations in his Natural History, recommending milk thistle for "liver ailments" and even as a remedy for poisoning. Ancient Greek physician Dioscorides prescribed it for serpent bites, while Pliny the Elder recommended mixing the juice with honey to "carry off bile." Roman scholars documented using milk thistle for liver and gallbladder complaints as early as the first century.

Use in medieval European herbal medicine was sustained and expanded. Medieval healers and herbalists often used this herb for jaundice, liver congestion and insect stings — cementing it as a staple for health in traditional medicine. In medieval Europe, milk thistle was used as an herbal remedy for exposure to certain toxins, particularly from mushrooms, highlighting its historical connection to liver protection. It was a staple in ancient herbal medicine, finding widespread use in the Middle East, India, and Europe.

The transition from traditional use to formal medical recognition occurred in the twentieth century. Since the 1970s, flavonolignans presented in silymarin have been regarded in official medicine as substances having hepatoprotective properties. A team of German researchers, curious about milk thistle's long-standing reputation for liver health, set out to identify its active ingredients. They suspected that the plant's seeds, which medieval herbalists had prioritized, held the key. Regulatory recognition followed: in 2018, the European Medicines Agency published an assessment report on the oral use of milk thistle fruit and its extracts in EU states. It finds that there is a "well-established use" of hepatoprotection approved by 11 countries and a "traditional use" of dyspeptic complaints in 4 countries. EMA has also published a monograph on this herbal substance.

5. Mechanisms of Action

5.1 Antioxidant Mechanisms

Silymarin flavonolignans — principally silybin A/B, isosilybin, silychristin, and silydianin — counteract oxidative cascades through at least three complementary mechanisms: (i) direct radical scavenging and iron chelation that interrupt lipid peroxidation chains; (ii) electrophile-mediated activation of the Keap1/NRF2/ARE axis, upregulating endogenous antioxidant enzymes (NQO1, HO-1, GCLC) and restoring glutathione reserves; and (iii) context-dependent modulation of NF-κB inflammatory signalling, reducing cytokine-driven amplification of oxidative injury.

The Nrf2 pathway is particularly well characterized. Some identified phytochemicals from silymarin had shown to participate in the Nrf2 signaling pathway; in particular, they have been suggested as activators that disrupt interactions in the Keap1–Nrf2 system, but also as antioxidants or with additional actions regarding Nrf2 regulation. The mechanism by which silymarin compounds exert their effect has been suggested to be by disrupting the complex between Nrf2 and Kelch-like ECH-associated protein 1 (Keap1).

Three principal antioxidant mechanisms have been summarized as follows: (1) Direct scavenging of free radicals and chelating free iron and copper are mainly effective in the gut. (2) Preventing free radical formation by inhibiting specific ROS-producing enzymes, or improving an integrity of mitochondria in stress conditions, are of great importance. (3) Maintaining an optimal redox balance in the cell by activating a range of antioxidant enzymes and non-enzymatic antioxidants, mainly via Nrf2 activation, is probably the main driving force of antioxidant action of silymarin.

5.2 Anti-inflammatory Mechanisms

Silymarin exerts a very strong anti-inflammatory action by inhibiting NF-κB and reducing leukotriene synthesis by inhibiting the 5-LOX pathway. Flavonolignans modulate a variety of cell-signaling pathways as well as inhibit arachidonic acid metabolism, resulting in the reduction of pro-inflammatory mediators formation.

5.3 Antifibrotic Mechanisms

Silymarin exerts antifibrotic effects by retarding conversion of hepatic stellate cells into myofibroblasts. This action is relevant to the prevention of hepatic fibrosis and cirrhosis progression, which are key endpoints studied in clinical trials. Silymarin acts as a free radical scavenger and modulates enzymes associated with the development of cellular damage, fibrosis and cirrhosis.

5.4 Broader Signaling Pathway Interactions

Mechanistic studies have clarified that silymarin's major bioactive constituents, like silibinin, silydianin, and silychristin, interact with redox-sensitive transcriptional pathways such as Nrf2/ARE and NF-κB, while also influencing metabolic regulators like AMPK and SIRT1. These mechanisms collectively work for their antioxidant, anti-inflammatory, and antifibrotic actions.

By attenuating MAPK–ERK and PI3K/Akt/mTOR signalling cascades, silymarin reduces oxidative stress, thereby prolonging hepatocellular survival and optimising pharmacokinetic stability through improved metabolic resilience.

Recent mechanistic evidence suggests that these pathways converge on mitochondrial protection and the regulation of oxidative phosphorylation, contributing to their dual hepatocellular and neuroprotective actions.

5.5 Inhibition of Hepatitis C Virus

Silymarin, also known as milk thistle extract, inhibits hepatitis C virus (HCV) infection and also displays antioxidant, anti-inflammatory, and immunomodulatory actions that contribute to its hepatoprotective effects. Activities tested included inhibition of: HCV cell culture infection, NS5B polymerase activity, TNF-alpha-induced NF-kappaB transcription, virus-induced oxidative stress, and T-cell proliferation.

5.6 Anticoagulant Activity

Research has demonstrated that the major flavonolignan silybin is able to inhibit two blood coagulation factors: thrombin and FXa.

5.7 Antimicrobial Activity

Research in 2022 concluded that flavonolignans "reduce the virulence of antibiotic-resistant bacterial strains."

6. Scientific Evidence by Area of Use

6.1 Hepatoprotection and Liver Disease

This is the most studied area for silymarin flavonolignans and the one with the strongest clinical evidence base. Silymarin acts by antioxidative, anti-lipid peroxidative, antifibrotic, anti-inflammatory, membrane stabilizing, immunomodulatory and liver regenerating mechanisms. Silymarin has clinical applications in alcoholic liver diseases, liver cirrhosis, Amanita mushroom poisoning, viral hepatitis, toxic and drug induced liver diseases and in diabetic patients.

Meta-analytic and systematic review evidence: Of 1,707 initially identified articles, 29 RCTs met the inclusion criteria in one systematic review, encompassing 3,846 participants with diverse underlying conditions. Hepatoprotective effects were observed in clinical studies in patients with alcoholic or non-alcoholic fatty liver disease, including patients with cirrhosis. In a pooled analysis of trials in patients with cirrhosis, silymarin treatment was associated with a significant reduction in liver-related deaths.

NAFLD/NASH: Recently, randomized clinical trials have been conducted examining the efficacy of silymarin in individuals with NAFLD, with conflicting results. A systematic review with meta-analysis including six clinical trials showed that silymarin reduced serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in NAFLD patients, but the studies appraised in that meta-analysis had significant methodological variability. A few studies have pointed out a beneficial effect of silymarin therapy upon the evolution of NAFLD, but significant variability and methodological differences across available studies prevent the establishment of robust conclusions.

Alcoholic liver disease: One meta-analysis of silibinin capsules against alcoholic liver disease included 15 RCTs conducted between inception and 2023, involving 1,221 patients. Among these studies, 13 RCTs were conducted in China, while 2 were conducted in Hungary and Austria. Silibinin has been shown to protect liver cells through various pharmacological pathways such as enhancing hepatocyte membrane stability, antioxidation, antifibrosis, and anti-inflammation.

Liver enzyme levels: Silymarin offers protective effects on the liver and shows promise in improving liver function and histological outcomes in various chronic liver conditions. Despite the promising results, further research is needed to fully elucidate the optimal dosing regimens, long-term safety, and potential drug interactions of silymarin.

Evidence characterization: The EMA's assessment recognizes "well-established use" for hepatoprotection (approved by 11 EU countries), which represents one of the stronger regulatory endorsements for a botanical in the European context. However, many individual trials suffer from small sample sizes, short durations, and variable standardization of the extract used, meaning that the overall body of clinical evidence — while positive — is not yet at the level of a fully validated pharmaceutical intervention for most liver conditions.

6.2 Metabolic Disorders: Type 2 Diabetes and Insulin Resistance

A growing number of RCTs and meta-analyses have examined silymarin's effects on glycemic parameters. In a systematic review and meta-analysis including five randomized controlled trials and 270 patients, routine silymarin administration determines a significant reduction in fasting blood glucose levels (−26.86 mg/dL; 95% CI −35.42–18.30) and HbA1c levels (−1.07; 95% CI −1.73–0.40) and has no effect on lipid profile. However, being aware of the low quality of the available evidence and elevated heterogeneity of these studies, no recommendation can be made and further studies are needed.

A more recent meta-analysis confirmed some of these findings but also identified limitations. Meta-analysis showed that Silybum marianum significantly improved HOMA-IR (WMD = −2.29, 95% CI: −4.55 to −0.03, p = 0.047) but had no effect on fasting insulin (WMD = −2.56, 95% CI: −7.60 to 2.48, p = 0.862). Subgroup analyses revealed improvements in HOMA-IR for T2DM and diabetics with alcoholic cirrhosis, but no effect in NAFLD patients. QUICKI did not show significant changes in any group. In conclusion, the results of this study indicate that there is limited evidence supporting the effectiveness of silymarin in improving HOMA-IR and FI levels in metabolic diseases.

A further meta-analysis of seven clinical trials (350 patients) reported that silymarin supplementation can decrease fasting blood sugar (FBS), hemoglobin A1C (HbA1C), and low density lipoprotein cholesterol (LDL-C), but it has no effect on total cholesterol (TC) or total triglyceride (TG). The mechanistic basis for these effects involves silybin's metabolic actions: silybin improves glycemic homeostasis by positively affecting the activity of pancreatic β-cells, increasing insulin sensitivity of liver and muscle cells, while decreasing lipid deposition in adipocytes.

Evidence characterization: Evidence in T2DM is moderate in quantity but methodologically heterogeneous. Glycemic improvements (FBS, HbA1c) show a statistically significant signal across meta-analyses, but effect sizes are moderate and study quality is variable. Results in NAFLD-associated insulin resistance are less consistent.

6.3 Neurological and Neuroprotective Effects

In the last 10–15 years, several research studies have shown the putative neuroprotective nature of silymarin against various brain disorders, including psychiatric, neurodegenerative, cognitive, metabolic and other neurological disorders.

Recent research shows that it has a neuroprotective role in different neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, epilepsy, cerebral ischemia and multiple sclerosis. These neuroprotective effects of silymarin are attributed to its anti-inflammatory, antioxidant, anti-cancer, cardio-protective, radioprotective and anti-apoptotic activities in the biological systems.

Recent mechanistic evidence suggests that these pathways converge on mitochondrial protection and the regulation of oxidative phosphorylation, contributing to their dual hepatocellular and neuroprotective actions.

Evidence characterization: Neuroprotective evidence for silymarin flavonolignans in humans is predominantly preclinical (animal models and cell lines). A review covering PubMed, EMBASE, and ScienceDirect up to January 2023 found mostly animal and in-vitro data, with very limited human clinical trials specifically for neurodegenerative endpoints. This area should be considered preliminary.

6.4 Oncology (Cancer)

With respect to cancer, silybin has been shown to inhibit various cancer cell types by modulating multiple processes, including growth inhibition, inhibition of angiogenesis, chemosensitization, and modulation of metastatic capacity.

Their ability to interact with proteins involved in drug resistance, and to enhance the effects of conventional chemotherapeutics in decreasing cell viability make them influential partners in addressing cancer. Specific flavonolignan subgroups including those derived from isoflavonoids and aurones have also been investigated. While the main focus falls on flavonolignans from milk thistle, attention is drawn to the yet underexplored potential of less known flavonolignan subgroups derived from isoflavonoids and aurones.

Silymarin has also demonstrated efficacy in preventing chemotherapy-induced adverse effects such as hand–foot syndrome and oral mucositis.

In 2019, Cancer Research UK stated: "We need a lot more research with reliable clinical trials before we can be sure that milk thistle will play any part in treating or preventing cancers."

Evidence characterization: The anticancer evidence for silymarin/silybin is predominantly in vitro and in animal models. Human clinical evidence is sparse and mostly limited to supportive or adjunctive use (e.g., reducing chemotherapy toxicity). No robust clinical trial evidence supports the use of flavonolignans as a primary anticancer therapy in humans.

6.5 Cardiometabolic and Cardioprotective Effects

The newest findings regarding the pharmacokinetics, hepatoprotective, antiviral, neuroprotective, and cardioprotective activity, modulation of endocrine functions, modulation of multidrug resistance, and safety of flavonolignans are discussed in review literature. Silymarin and its major active flavonolignan silybin also have promising effects in protecting the pancreas, kidney, myocardium, and the central nervous system.

Evidence characterization: Cardioprotective effects are supported by preclinical data and mechanistic plausibility. Clinical evidence specific to cardiac endpoints in humans is limited and has not yet been established through adequately powered RCTs.

7. Pharmacokinetics and Bioavailability

Oral bioavailability of silymarin flavonolignans is substantially limited by multiple barriers. Oral absorption of silymarin, particularly silybin, is severely restricted by multiple factors: poor aqueous solubility, low membrane permeability, active efflux by intestinal transporters (e.g., P-gp, BCRP), chemical instability under gastrointestinal pH, extensive first-pass glucuronidation/sulfation, rapid biliary excretion, and pharmacokinetic divergence among flavonolignans. Together, these barriers result in extremely low bioavailability (~0.45%), underscoring the need for formulation strategies that enhance solubility, permeability, efflux inhibition, and metabolic stability.

There are two known major reasons for poor systemic oral bioavailability of flavonolignans: (1) rapid conjugation in intestinal cells or the liver and (2) efflux of parent flavonolignans or formed conjugates back to the lumen of the gastrointestinal tract by intestinal cells and rapid excretion by the liver into the bile.

After absorption, silymarin undergoes extensive biotransformation. After oral administration, silybin/silymarin undergoes both phase I and phase II biotransformation, especially the latter. Phase I metabolites of silybin mainly include O-demethylated ones mediated by the CYP2C8 isoenzyme. Silybin and its phase I metabolites undergo extensive phase II biotransformation, as most of the silybin in the system exists as conjugates including 55% glucuronidated conjugates and about 28% sulfated ones. Glucuronidation reactions of silybin are mediated by UDP-glucuronosyltransferase (UGT)1A1, 1A6, 1A7, 1A9, 2B7, and 2B15, while sulfidation reactions are mediated by sulfotransferases (SULTs).

The major efflux transporters of silybin are multidrug resistance-associated protein (MRP2) and breast cancer resistance protein (BCRP) based on results from transporter-overexpressing cell lines and MRP2-deficient (TR−) rats.

Excretion is primarily biliary. Silymarin is orally absorbed and is excreted mainly through bile as sulphates and conjugates.

8. Dosage Forms and Preparations

Flavonolignans, most commonly as silymarin extract, are available in multiple forms. Silymarin is extracted from the seeds, commercialized in standardized form, and widely used in drugs and dietary supplements. Commercially, products typically present as capsules, tablets, softgels (including phytosomal formulations), liquid extracts, and teas.

Standard extracts are typically standardized to 70–80% silymarin content. Silymarin, a flavonoid complex, is the main constituent with 70–80% of the extract from seeds of the milk thistle.

Dosages reported in clinical studies:

Silymarin is safe in humans at therapeutic doses and is well tolerated even at a high dose of 700 mg three times a day for 24 weeks.
Dosing regimens for silybin range from an equivalence of 140 mg of standardized silymarin daily to 900 mg daily.
According to the findings of clinical trials, silymarin is safe in humans at higher doses (over 1,500 mg/day) and no serious side effects have been reported.
One NAFLD protocol used 700 mg of silymarin + 8 mg vitamin E + 50 mg phosphatidylcholine daily as the active intervention.

Advanced Delivery Systems to Enhance Bioavailability

Given the low native bioavailability, a range of advanced formulations have been developed and studied. Key innovations include nanotechnology-enabled delivery systems, lipid-based carriers, water-soluble derivatives, bioavailability enhancers, parenteral and transdermal formulations, as well as controlled and synchronous release technologies.

The best-studied advanced formulation is the silybin–phosphatidylcholine complex (phytosome). In a clinical pharmacokinetic study, a silymarin-phosphatidylcholine soft complex achieved a 9.6-fold increase in oral bioavailability compared to conventional silymarin tablets in healthy volunteers.

The proprietary preparation Eurosil 85® has been used in much of the formal clinical research. Eurosil 85® is a proprietary formulation developed to maximize the oral bioavailability of silymarin. Most of the clinical research on silymarin has used this formulation.

Various pharmaceutical formulations that aim at the bioavailability improvement of these phytochemicals include liposomes, phytosomes, self-microemulsifying drug delivery systems, solid dispersions systems, dripping pills, nanosuspensions, floating tablets, and others.

Intravenous silibinin preparations (e.g., Legalon® SIL) have also been studied, particularly for acute Amanita phalloides poisoning, though this represents a separate clinical context from the oral dietary supplement use discussed in this article.

9. Body Systems and Health Areas Associated with Flavonolignans

The range of body systems associated with flavonolignan research is broad. Extensive scientific research has investigated the therapeutic effects of silymarin on various diseases, including liver disorders, inflammatory diseases, cancer, neurological disorders, skin conditions, and hypercholesterolemia. Modern studies have further elucidated that silymarin exerts significant neuroprotective, hepatoprotective, cardioprotective, antioxidant, anticancer, antidiabetic, antiviral, antihypertensive, immunomodulatory, anti-inflammatory, photoprotective, and detoxifying effects by acting on various cellular and molecular pathways (e.g., MAPK, mTOR, β-catenin, and Akt).

Key systems and areas include:

Hepatic (Liver): Primary area of established use; hepatoprotection, antifibrotic, supportive care in cirrhosis, alcoholic liver disease, NAFLD/NASH, drug-induced liver injury, and Amanita mushroom poisoning.
Metabolic / Endocrine: Glycemic regulation, insulin sensitization, lipid-lowering (LDL-C).
Nervous System: Neuroprotective activity investigated in Alzheimer's disease, Parkinson's disease, multiple sclerosis, and cognitive decline — primarily preclinical.
Cardiovascular: Cardioprotective effects in preclinical models; antihypertensive properties under investigation.
Immune System: Immunomodulatory activities, including modulation of T-cell proliferation and cytokine production.
Renal: Renoprotective effects studied particularly in the context of diabetic nephropathy.
Oncological (Adjunctive): Prevention of chemotherapy toxicity (hand-foot syndrome, mucositis); in-vitro antiproliferative evidence across multiple cancer cell types.

10. Safety Considerations and Drug Interactions

10.1 General Safety Profile

The frequency of adverse events reported from numerous clinical trials, testing a variety of milk thistle extract formulations (including silymarin and silibinin), in thousands of patients, is low. Most clinical trials reported no adverse events or no differences between placebo and treated groups. When adverse events were observed, they were generally considered minor, and included mild gastrointestinal symptoms (for example, dry mouth, nausea, upset stomach, gastric irritation, diarrhoea), headache, and/or sensitization reaction (such as dermatitis, urticaria, skin rash, pruritus).

In clinical trials, silymarin has a broad range of indications, with few serious adverse reactions, with occasional reports of insomnia. According to a meta-analysis by Zheng et al. (2022), the incidence of adverse reactions to silymarin capsules was low, about 7% overall, and not significantly different from the control group.

At the cellular level, silybin, silydianin, and silychristin were not cytotoxic and genotoxic at concentrations of 100 μM.

10.2 Drug–Drug Interactions and Cytochrome P450 Considerations

This is an area where in-vitro and in-vivo data diverge importantly. Several in vitro studies have suggested that silymarin extracts and various individual constituents inhibit CYP2D6, CYP2E1, CYP3A4, CYP2C9, and CYP2C8. Despite the apparent ability of milk thistle extracts to produce significant inhibition of one or more P450 enzymes as reported in several published in vitro studies, in vivo human data have been unable to replicate in vitro predictions.

Silymarin has a good safety profile, but little is known regarding its potential for drug interaction. Silymarin has limited effect on the pharmacokinetics of several drugs in vivo; despite silymarin decreasing the activity of cytochrome P-450 (CYPs) enzymes, UDP-glucuronosyltransferase (UGT) enzyme, and reducing P-glycoprotein (P-gp) transport.

In vitro inhibition of specific P450 isoforms has been characterized quantitatively: at 1 μM concentration no or negligible inhibition of cytochromes P450 1A2, 2A6, 2B6, 2C8, 2C9, and 2E1 were observed, with minor inhibition of 3A4 (<20%), and moderate inhibition of 2C19 and 2D6 (<40%). Inhibition constants Ki of silymarin were determined for cytochromes P450 3A4 at 12 μM, 2C19 at 2 μM, and 2D6 at 12 μM. However, in view of the clinically relevant plasma concentration of approximately 0.2 μM measured as silibinin, it is evident that there is no drug–drug interaction problem with silymarin at typical therapeutic concentrations.

While there is some evidence of inhibitory effects of milk thistle extract on cytochrome P450 (CYP450) and uridine 5′-diphospho-glucuronosyltransferase (UGT) activity in vitro, several reviews have concluded that the concentrations at which inhibition is observed are extremely high, and generally not achievable with oral intake.

The broader efflux transporter profile is also relevant: active efflux by intestinal transporters including P-gp and BCRP limits absorption. Because silymarin can interact with these transporters, co-administration with drugs that are also substrates of P-gp or BCRP requires consideration, though clinical impact at standard doses appears to be minimal based on current data.

10.3 Chirality and Differential Activity of Diastereomers

A growing number of studies show that the respective diastereomers of flavonolignans have significantly different activities in anisotropic biological systems. This is particularly relevant for silybin (A and B diastereomers) and isosilybin (A and B diastereomers), and has implications for interpreting study results that use racemic or mixed preparations, as opposed to purified individual stereoisomers.

10.4 Biosynthesis and Chemotype Variation

The exact ratio and total content of flavonolignans varies between plant chemotypes. Besides differences in total silymarin content (0.8%–4.9%), three distinct chemotypical variations in fruit flavonolignan regioisomer composition in the cultivars have been observed. Genetic and metabolic engineering efforts are directed toward enhancing flavonolignan biosynthesis, optimising industrial-scale production, and ensuring consistency in therapeutic formulations. This chemotypic variability is a recognized source of inter-product inconsistency and a confounder in clinical research.

11. Regulatory and Research Context

In 2018, the European Medicines Agency published an assessment report on the oral use of milk thistle fruit and its extracts in EU states, finding that there is a "well-established use" of hepatoprotection approved by 11 countries and a "traditional use" of dyspeptic complaints in 4 countries.

Since the 1970s, flavonolignans presented in silymarin have been regarded in official medicine as substances having hepatoprotective properties. Silymarin, a flavonolignan from milk thistle, is used almost exclusively for hepatoprotection and amounts to 180 million US dollars business in Germany alone.

Inconsistent results are noted in the different clinical studies due to the low bioavailability of silymarin — a factor that complicates direct comparison across trials using different formulations and doses. Further research is needed to fully elucidate the optimal dosing regimens, long-term safety, and potential drug interactions of silymarin.

Research attention has historically been heavily concentrated on silybin to the relative exclusion of other flavonolignans. Cumulative PubMed-indexed publications (1960–2025) mentioning individual silymarin components show publication counts reflecting a strong bias toward silybin compared to silychristin, silydianin, and the isosilybin isomers, which remain comparatively undercharacterized despite distinct biological activity profiles.

References

Health Conditions

Health conditions that Flavonolignan may help support.

No conditions available.

Body Systems

Body systems that Flavonolignan may help support.

No body systems available.